期刊文献+

激素诱发骨坏死的机制:随机对照研究 被引量:4

Mechanism of osteonecrosis induced by provoke bone-loss:a rondomized control study
下载PDF
导出
摘要 目的:探讨糖皮质激素诱发骨坏死的机制。方法:将兔复制Yamamoto氏骨坏死模型,分为对照组(4只),2,4,6和8周组,每组各5只,按照不同时间处死取材。利用双光子骨密度仪测量股骨头部的骨质密度值。收集激素性骨坏死患者的病理标本21例,以无骨代谢疾病患者的股骨标本为对照,免疫组化染色观察激素性骨坏死股骨头局部骨保护素(OPG)/破骨细胞生成抑制因子(OCIF)蛋白的表达改变。结果:糖皮质激素给药后,继发于OPG表达减低(P<0.01)和破骨细胞异常增生后,局部出现渐进性骨丢失(P<0.05);与正常对照比较,激素性骨坏死患者的股骨头局部OPG表达明显减低(P<0.05)。结论:糖皮质激素抑制骨骼局部的OPG表达,使破骨细胞异常增殖,从而出现骨丢失。 AIM:To study the mechanism of glucocorticoid(GG) induced osteonecrosis. METHODS: According to the Yamamoto's method, a model of GG induced osteonecros is was reproduced in 24 New Zealand rabbits by administration with GG.The rabbit s were divided into control group(n=4),2,4,6 and 8 weeks groups(n=5 respectively ),and they were kill for materials according to different time.The bone mineral density in femoral head was measured by using the dual photon bone densitimetry. The biopsy samples from 21 patients with glucocorticoid induced osteonecrosis an d a healthy volunteer were collected to examine the local expression level of os teoprotegerin.The changes of local osteoprotegerin(OPG) expression of osteonevro sis in femoral head and osteoclast cell inhibitive factor(OCIF) protein expressi on were observed by immunohistochemical staining. RESULTS:After the administration of GG,the local OPG expression reduced(P< 0.0 1) and the number of osteoclasts abnormally increased,followed by the aggravated bone-loss in the Yamamoto's model(P< 0.05). The local OPG expression of osteon ecrosis patients was obviously lower than that of the healthy control subject(P< 0.05). CONCLUSION:Glucocorticoid inhibits the local OPG expression of bone,and facili tates abnormal proliferation of osteoclasts which results in bone-loss.
出处 《中国临床康复》 CSCD 2004年第15期2900-2901,共2页 Chinese Journal of Clinical Rehabilitation
基金 国家自然科学基金面上资助项目(30170948).
  • 相关文献

参考文献7

  • 1Yamamoto T, Hirano K, Tsutsui H, et al. Corticosteroid enhances the experimental induction of osteonecrosis in rabbits with shwartzman reaction. Clinical Orthop 1995; (316): 235-43
  • 2Simonet WS, Lacey DL, Cunstan CR, et al. Osetoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997; 89:309-19
  • 3Yasuda H, Shima N, Nakagawa N, et al. A Novel Molelar mechanism modulating osteoclast differentiation and function. Bone 1999;25:109-13
  • 4Yasuda H, Shima N, Nakagawa N, et al. Identity of Osteoclastogenesis inhibitory factor(OCIF) and osteoprotegerin(OPG): A mechanism by which OPG/OCIFinhibits osteoclastogenesis in vitro. Endocrinology 1998; 139:1329-37
  • 5Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93:165-76
  • 6Hofbauer LC, Gorl F, Riggs BL, et al. timulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocoticoid-induced osteoporosis. Endocrino
  • 7Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion apoptosis of osteoblasts and osteocytes by glucocoticoids. J Clin Inves 1998; 102(2): 274-82

同被引文献57

引证文献4

二级引证文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部